Paul Yien Kwo, MD
Gastroenterology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Offices
- 7
Offices
7 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Clovis Community Medical Center · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kwo’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G145613 · Current
Licensed to practise in California · since 2016 · expires 2027-12-31 · Wayne State University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Clovis Community Medical CenterClovis, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 80% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.7 (12.1 to 17.7) · 421 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.692, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Clovis Community Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 6 the same, 1 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.7 (12.1 to 17.7) · 421 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.692 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0.04 to 1.89) · 1,840 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.16 (0.86 to 1.45) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 217.06 (167.45 to 266.67) · 84 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.4 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14 · 507 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 798 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 336 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 3,771 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 8,649 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.08 to 0.46) · 9,146 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.46 (1.47 to 5.45) · 1,654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.19 (0.61 to 3.78) · 387 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.18 (0.7 to 3.66) · 1,578 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.47 (7.08 to 19.87) · 374 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.99 (1.37 to 8.61) · 379 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.04) · 405 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.8 (0.23 to 1.38) · 8,198 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 90 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.922 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.449 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.509 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 210 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -1.5 · 152 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 58.4 · 556 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18 · 769 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 802 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (4 to 7.4) · 421 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 91 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 93 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.8 to 15.6) · 2,398 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 720 cases | No different | Jan 2024 – Dec 2024 |
What patients said (441 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 80% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$60,689
Medicare paid this office $60,689 for 388 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 197 | $20,610 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 37 | $8,824 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $4,190 | $105 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $3,035 | $117 |
| Return visit (30+ min) | 25 | $2,960 | $102 |
See all 15 services
| Short return visit (20+ min) | 197 | $20,610 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 37 | $8,824 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $4,190 | $105 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $3,035 | $117 |
| Return visit (30+ min) | 25 | $2,960 | $102 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 12 | $2,836 | $236 |
| New patient visit (30+ min) | 36 | $2,580 | $72 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 19 | $1,968 | $98 |
| New patient visit (45+ min) | 13 | $1,409 | $108 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,105 | $100 |
| Biopsy of large bowel using a flexible endoscope | 13 | $1,055 | $81 |
| Biopsy of large bowel using a flexible endoscope | 11 | $1,020 | $93 |
| Short return visit | 19 | $830 | $41 |
| Measurement of liver stiffness | 80 | $697 | $9 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 42 | $608 | $14 |
Procedures Medicare counted
| Colonoscopy | 11 | More than 41% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 35 | More than 58% of doctors who do this |
Who their Medicare patients are
388 Original Medicare patients in 2024. Average age 70 · Under 65 17% · 85 and older 6% · Women 55% · Also on Medicaid 39% · Health risk score 2.34. Sicker patients than 9 in 10 peers; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 74% · Diabetes 39% · Chronic kidney disease 31% · Coronary heart disease 30% · Heart failure 20% · Depression 20% · Atrial fibrillation 19% · Cancer 15% · COPD 15% · Stroke 7% · Dementia 6%.
The office billed $423,343, Medicare allowed $79,511 and paid $60,689; for 849 services of 29 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 388 | 849 | 70 | 2.34 | $423,343 | $60,689 |
| 2023 | 383 | 843 | 69 | 2.38 | $332,010 | $58,003 |
| 2022 | 326 | 733 | 70 | 2.31 | $339,149 | $49,213 |
| 2021 | 271 | 646 | 68 | 2.48 | $302,879 | $46,675 |
| 2020 | 299 | 716 | 67 | 2.59 | $320,477 | $45,622 |
| 2019 | 255 | 652 | 67 | 2.52 | $217,340 | $43,533 |
| 2018 | 240 | 642 | 67 | 2.81 | $279,598 | $45,719 |
| 2017 | 162 | 413 | 65 | 2.77 | $134,730 | $29,963 |
| 2016 | 460 | 950 | 64 | 2.64 | $206,731 | $51,751 |
| 2015 | 474 | 1,134 | 63 | 2.54 | $261,501 | $62,767 |
| 2014 | 505 | 1,259 | 63 | 2.28 | $282,401 | $70,661 |
| 2013 | 479 | 1,310 | 63 | 2.58 | $292,286 | $74,089 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 51 | $14,702 | $72 |
| Short return visit (20+ min) | 166 | $12,562 | $57 |
| New patient visit (30+ min) | 65 | $5,270 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $4,606 | $110 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $3,103 | $119 |
| Short return visit (20+ min) | 27 | $2,870 | $55 |
| Hospital discharge day management, 30 minutes or less | 21 | $1,746 | $76 |
| New patient visit (45+ min) | 12 | $1,722 | $144 |
| Return visit (30+ min) | 11 | $1,277 | $91 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 25 | $691 | $28 |
| Measurement of liver stiffness | 71 | $648 | $9 |
| Telehealth originating site facility fee | 14 | $303 | $22 |
2022: 9 services
| Short return visit (20+ min) | 145 | $12,675 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $7,042 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $4,297 | $93 |
| New patient visit (45+ min) | 30 | $3,730 | $124 |
| Short return visit (20+ min) | 27 | $3,418 | $57 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $2,821 | $123 |
| New patient visit (30+ min) | 20 | $1,867 | $93 |
| Measurement of liver stiffness | 65 | $590 | $9 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 17 | $520 | $31 |
2021: 9 services
| Short return visit (20+ min) | 137 | $14,069 | $60 |
| New patient visit (45+ min) | 38 | $5,501 | $145 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $4,570 | $66 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 27 | $3,406 | $126 |
| Short return visit (20+ min) | 25 | $3,152 | $54 |
| Return visit (30+ min) | 15 | $1,546 | $97 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,173 | $107 |
| Measurement of liver stiffness | 49 | $421 | $8 |
| Telehealth originating site facility fee | 16 | $335 | $21 |
2020: 11 services
| Short return visit (20+ min) | 146 | $11,628 | $45 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 45 | $7,788 | $67 |
| New patient visit (45+ min) | 39 | $4,513 | $116 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 27 | $3,554 | $127 |
| Short return visit (20+ min) | 27 | $2,093 | $44 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,442 | $96 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $1,429 | $102 |
| Return visit (30+ min) | 11 | $873 | $79 |
| Telephone medical discussion with physician, 11-20 minutes | 16 | $871 | $54 |
| Telehealth originating site facility fee | 34 | $812 | $21 |
| Measurement of liver stiffness | 23 | $294 | $12 |
2019: 9 services
| Short return visit (20+ min) | 123 | $9,380 | $43 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 38 | $7,862 | $65 |
| New patient visit (45+ min) | 54 | $6,557 | $121 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $2,678 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $2,415 | $93 |
| Short return visit (20+ min) | 25 | $2,231 | $45 |
| Return visit (30+ min) | 21 | $1,667 | $72 |
| Return visit (30+ min) | 18 | $1,344 | $71 |
| Measurement of liver stiffness | 28 | $320 | $11 |
2018: 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 60 | $11,035 | $65 |
| Short return visit (20+ min) | 71 | $4,244 | $43 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 33 | $4,141 | $122 |
| Short return visit (20+ min) | 62 | $3,819 | $48 |
| New patient visit (45+ min) | 30 | $3,747 | $125 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 11 | $2,449 | $223 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $2,245 | $94 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | $2,228 | $97 |
| New patient visit (45+ min) | 18 | $1,624 | $90 |
| Return visit (30+ min) | 15 | $1,342 | $71 |
| Hospital discharge day management, 30 minutes or less | 19 | $1,270 | $67 |
| Biopsy of large bowel using a flexible endoscope | 11 | $834 | $76 |
| Measurement of liver stiffness | 13 | $166 | $13 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 19 | $91 | $5 |
2017: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $6,404 | $65 |
| New patient visit (45+ min) | 53 | $5,764 | $109 |
| Short return visit (20+ min) | 62 | $3,833 | $44 |
| Return visit (30+ min) | 25 | $2,398 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $2,244 | $93 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,578 | $121 |
| Long return visit (40+ min) | 12 | $1,098 | $91 |
| Measurement of liver stiffness | 23 | $251 | $11 |
2016: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 58 | $12,069 | $54 |
| Short return visit (20+ min) | 216 | $9,222 | $33 |
| Short return visit (20+ min) | 86 | $5,126 | $47 |
| Return visit (30+ min) | 70 | $4,665 | $50 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 43 | $4,600 | $102 |
| New patient visit (45+ min) | 29 | $2,440 | $84 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $1,536 | $90 |
| Hospital discharge day management, 30 minutes or less | 26 | $1,455 | $52 |
| Long return visit (40+ min) | 16 | $1,294 | $81 |
| Return visit (30+ min) | 14 | $1,115 | $74 |
2015: 13 services
| Short return visit (20+ min) | 264 | $13,153 | $35 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 45 | $11,697 | $55 |
| Short return visit (20+ min) | 119 | $7,111 | $41 |
| Return visit (30+ min) | 69 | $5,329 | $55 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 16 | $3,718 | $232 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 31 | $3,349 | $101 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 30 | $2,806 | $88 |
| New patient visit (45+ min) | 26 | $2,462 | $95 |
| Biopsy of large bowel using a flexible endoscope | 17 | $1,855 | $109 |
| Hospital discharge day management, 30 minutes or less | 25 | $1,385 | $55 |
| Return visit (30+ min) | 17 | $1,196 | $63 |
| Long return visit (40+ min) | 12 | $1,016 | $85 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 15 | $565 | $30 |
2014: 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 60 | $14,157 | $55 |
| Short return visit (20+ min) | 267 | $13,333 | $36 |
| Short return visit (20+ min) | 117 | $8,060 | $46 |
| Return visit (30+ min) | 96 | $7,831 | $56 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 50 | $4,259 | $84 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 35 | $4,165 | $104 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 11 | $2,556 | $232 |
| New patient visit (45+ min) | 18 | $1,771 | $98 |
| Biopsy of large bowel using a flexible endoscope | 13 | $1,724 | $133 |
| Hospital discharge day management, 30 minutes or less | 29 | $1,698 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,576 | $79 |
| Return visit (30+ min) | 17 | $1,052 | $50 |
| Short return visit | 23 | $477 | $18 |
2013: 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 79 | $17,514 | $51 |
| Return visit (30+ min) | 132 | $10,867 | $54 |
| Short return visit (20+ min) | 223 | $10,628 | $34 |
| Short return visit (20+ min) | 105 | $7,130 | $48 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 44 | $4,352 | $93 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 38 | $3,874 | $97 |
| Biopsy of large bowel using a flexible endoscope | 16 | $2,425 | $152 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,114 | $151 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $1,994 | $77 |
| Hospital discharge day management, 30 minutes or less | 34 | $1,982 | $54 |
| New patient visit (45+ min) | 20 | $1,821 | $91 |
| Long return visit (40+ min) | 18 | $1,295 | $68 |
| Return visit (30+ min) | 21 | $1,192 | $48 |
Medicaid work
$23,576 in 2024
Medicaid paid $23,576 for 420 billed services this clinician did in 2024, up to 34 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 167 | $14,969 |
| Short return visit (20+ min) | 162 | $6,011 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 60 | $1,893 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 31 | $704 |
| 2024 | 420 | 4 | 34 | $23,576 |
| 2023 | 673 | 4 | 42 | $16,525 |
| 2022 | 484 | 4 | 36 | $13,324 |
| 2021 | 315 | 2 | 32 | $8,075 |
| 2020 | 398 | 2 | 36 | $11,220 |
| 2019 | 292 | 2 | 30 | $6,922 |
| 2018 | 233 | 2 | 30 | $6,445 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 315 | $6,898 |
| Short return visit (20+ min) | 254 | $5,701 |
| Return visit (30+ min) | 74 | $2,772 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 30 | $1,154 |
2022
| Short return visit (20+ min) | 359 | $8,516 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 85 | $3,188 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 28 | $1,502 |
| Liver elastography, mechanically induced shear wave (eg, vibration), without imaging, with interpretation and report | 12 | $118 |
2021
| Short return visit (20+ min) | 253 | $6,308 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 62 | $1,768 |
2020
| Short return visit (20+ min) | 282 | $6,826 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 116 | $4,393 |
2019
| Short return visit (20+ min) | 257 | $5,476 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 35 | $1,446 |
2018
| Short return visit (20+ min) | 197 | $5,134 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 36 | $1,311 |
Drugs they prescribed that Part D paid
$367,734
Pharmacies billed $367,734 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,000) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
851 generic and 149 brand-name prescriptions · $367,734 in drug cost · 47 antibiotic prescriptions to 13 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xifaxan | 34 | $110,724 | $3,257 |
| Vemlidy | 63 | $94,556 | $1,501 |
| Mycophenolate Mofetil | 87 | $16,844 | $194 |
| Entecavir | 62 | $12,791 | $206 |
| Mycophenolic Acid | 12 | $9,159 | $763 |
See all 22 drugs
| Xifaxan | 34 | $110,724 | $3,257 |
| Vemlidy | 63 | $94,556 | $1,501 |
| Mycophenolate Mofetil | 87 | $16,844 | $194 |
| Entecavir | 62 | $12,791 | $206 |
| Mycophenolic Acid | 12 | $9,159 | $763 |
| Ursodiol | 73 | $8,302 | $114 |
| Tacrolimus | 62 | $7,289 | $118 |
| Cyclosporine Modified | 37 | $6,224 | $168 |
| Tenofovir Disoproxil | 14 | $3,622 | $259 |
| Lansoprazole | 24 | $2,262 | $94 |
| Spironolactone | 41 | $515 | $13 |
| Peg 3350-Electrolyte | 24 | $465 | $19 |
| Lactulose | 16 | $443 | $28 |
| Fludrocortisone Acetate | 34 | $355 | $10 |
| Carvedilol | 65 | $337 | $5 |
| Pantoprazole | 39 | $324 | $8 |
| Esomeprazole Magnesium | 12 | $246 | $21 |
| Potassium Chloride | 19 | $242 | $13 |
| Furosemide | 33 | $167 | $5 |
| Omeprazole | 17 | $151 | $9 |
| Prednisone | 35 | $112 | $3 |
| Amlodipine Besylate | 17 | $59 | $3 |
Year by year
| 2024 | 1,000 | 164 | 0% (0) | 15% | $367,734 |
| 2023 | 810 | 130 | None | 11% | $209,912 |
| 2022 | 758 | 118 | 0% (0) | 18% | $256,034 |
| 2021 | 679 | 108 | 0% (0) | 23% | $335,275 |
| 2020 | 670 | 121 | None | 25% | $503,304 |
| 2019 | 559 | 112 | None | None | $336,415 |
| 2018 | 400 | 106 | None | None | $651,155 |
| 2017 | 738 | 193 | None | 24% | $842,770 |
| 2016 | 3,520 | 360 | 1% (46) | None | $4,330,715 |
| 2015 | 4,022 | 384 | 2% (84) | 28% | $9,978,656 |
| 2014 | 4,329 | 353 | 2% (92) | None | $9,403,774 |
| 2013 | 3,679 | 284 | 2% (69) | 28% | $1,057,929 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Xifaxan | 20 | $64,900 | $3,245 |
| Vemlidy | 26 | $42,887 | $1,650 |
| Tacrolimus | 50 | $11,503 | $230 |
| Ursodiol | 50 | $11,368 | $227 |
| Mycophenolate Mofetil | 79 | $11,203 | $142 |
| Entecavir | 52 | $9,981 | $192 |
| Mycophenolic Acid | 11 | $4,894 | $445 |
| Cyclosporine Modified | 31 | $4,717 | $152 |
| Lansoprazole | 13 | $1,218 | $94 |
| Azathioprine | 20 | $1,211 | $61 |
| Spironolactone | 31 | $1,034 | $33 |
| Fluconazole | 12 | $810 | $68 |
| Pantoprazole | 44 | $792 | $18 |
| Lactulose | 16 | $662 | $41 |
| Fludrocortisone Acetate | 34 | $546 | $16 |
| Carvedilol | 27 | $272 | $10 |
| Amlodipine Besylate | 24 | $257 | $11 |
| Peg 3350-Electrolyte | 12 | $236 | $20 |
| Prednisone | 29 | $233 | $8 |
| Metoprolol | 25 | $218 | $9 |
| Furosemide | 25 | $213 | $9 |
| Propranolol | 14 | $189 | $14 |
| Sulfamethoxazole-Trimethoprim | 13 | $65 | $5 |
2022: 23 drugs
| Xifaxan | 25 | $74,486 | $2,979 |
| Vemlidy | 30 | $43,852 | $1,462 |
| Sirolimus | 21 | $18,229 | $868 |
| Entecavir | 49 | $18,000 | $367 |
| Ozempic | 13 | $14,415 | $1,109 |
| Mycophenolic Acid | 18 | $12,898 | $717 |
| Ursodiol | 33 | $10,234 | $310 |
| Mycophenolate Mofetil | 50 | $6,056 | $121 |
| Tacrolimus | 37 | $5,674 | $153 |
| Cyclosporine Modified | 11 | $3,072 | $279 |
| Valganciclovir | 12 | $2,258 | $188 |
| Spironolactone | 65 | $1,861 | $29 |
| Bupropion Xl | 11 | $511 | $46 |
| Furosemide | 67 | $354 | $5 |
| Pantoprazole | 28 | $307 | $11 |
| Peg 3350-Electrolyte | 16 | $295 | $18 |
| Fludrocortisone Acetate | 16 | $209 | $13 |
| Carvedilol | 27 | $169 | $6 |
| Sulfamethoxazole-Trimethoprim | 13 | $141 | $11 |
| Metoprolol | 13 | $133 | $10 |
| Amlodipine Besylate | 31 | $130 | $4 |
| Metoprolol | 17 | $121 | $7 |
| Prednisone | 19 | $80 | $4 |
2021: 17 drugs
| Xifaxan | 36 | $109,564 | $3,043 |
| Vemlidy | 43 | $55,380 | $1,288 |
| Entecavir | 39 | $23,568 | $604 |
| Mycophenolic Acid | 12 | $12,550 | $1,046 |
| Mycophenolate Mofetil | 42 | $6,339 | $151 |
| Tacrolimus | 24 | $4,942 | $206 |
| Cyclosporine Modified | 22 | $4,671 | $212 |
| Ursodiol | 12 | $2,698 | $225 |
| Lactulose | 27 | $1,867 | $69 |
| Spironolactone | 77 | $1,760 | $23 |
| Potassium Chloride | 14 | $1,117 | $80 |
| Furosemide | 78 | $501 | $6 |
| Prednisone | 25 | $139 | $6 |
| Amlodipine Besylate | 20 | $130 | $7 |
| Fludrocortisone Acetate | 11 | $126 | $11 |
| Carvedilol | 12 | $113 | $9 |
| Bupropion Xl | 12 | $99 | $8 |
2020: 15 drugs
| Xifaxan | 27 | $68,605 | $2,541 |
| Vemlidy | 54 | $64,828 | $1,201 |
| Mycophenolic Acid | 14 | $17,184 | $1,227 |
| Entecavir | 48 | $15,759 | $328 |
| Mycophenolate Mofetil | 36 | $8,643 | $240 |
| Ursodiol | 17 | $4,386 | $258 |
| Cyclosporine Modified | 14 | $3,052 | $218 |
| Lactulose | 39 | $1,582 | $41 |
| Spironolactone | 54 | $1,416 | $26 |
| Furosemide | 71 | $456 | $6 |
| Omeprazole | 31 | $272 | $9 |
| Bupropion Xl | 12 | $199 | $17 |
| Carvedilol | 30 | $188 | $6 |
| Prednisone | 19 | $155 | $8 |
| Glipizide | 12 | $86 | $7 |
2019: 13 drugs
| Vemlidy | 37 | $50,624 | $1,368 |
| Xifaxan | 21 | $47,002 | $2,238 |
| Tacrolimus | 15 | $6,232 | $415 |
| Mycophenolate Mofetil | 33 | $6,201 | $188 |
| Entecavir | 61 | $5,432 | $89 |
| Ursodiol | 12 | $4,367 | $364 |
| Tenofovir Disoproxil | 13 | $2,622 | $202 |
| Cholestyramine | 15 | $1,703 | $114 |
| Spironolactone | 47 | $960 | $20 |
| Lactulose | 25 | $863 | $35 |
| Furosemide | 48 | $212 | $4 |
| Prednisone | 19 | $115 | $6 |
| Amlodipine Besylate | 14 | $56 | $4 |
2018: 9 drugs
| Vemlidy | 29 | $30,440 | $1,050 |
| Ursodiol | 25 | $8,029 | $321 |
| Entecavir | 15 | $3,973 | $265 |
| Spironolactone | 26 | $1,076 | $41 |
| Furosemide | 43 | $269 | $6 |
| Peg 3350-Electrolyte | 16 | $238 | $15 |
| Lactulose | 11 | $208 | $19 |
| Omeprazole | 19 | $160 | $8 |
| Sertraline | 11 | $62 | $6 |
2017: 22 drugs
| Epclusa | 19 | $483,148 | $25,429 |
| Xifaxan | 15 | $29,696 | $1,980 |
| Ursodiol | 55 | $18,439 | $335 |
| Tacrolimus | 63 | $15,664 | $249 |
| Viread | 14 | $15,159 | $1,083 |
| Entecavir | 14 | $13,001 | $929 |
| Prograf | 11 | $4,913 | $447 |
| Mycophenolate Mofetil | 25 | $2,991 | $120 |
| Neoral | 11 | $2,646 | $241 |
| Azathioprine | 15 | $1,149 | $77 |
| Omeprazole | 55 | $720 | $13 |
| Cyclosporine Modified | 13 | $696 | $54 |
| Lactulose | 15 | $552 | $37 |
| Fludrocortisone Acetate | 27 | $492 | $18 |
| Propranolol | 18 | $360 | $20 |
| Spironolactone | 33 | $359 | $11 |
| Pravastatin | 12 | $115 | $10 |
| Furosemide | 27 | $111 | $4 |
| Amlodipine Besylate | 17 | $108 | $6 |
| Sertraline | 14 | $107 | $8 |
| Pantoprazole | 13 | $103 | $8 |
| Levothyroxine | 19 | $90 | $5 |
2016: 58 drugs
| Harvoni | 61 | $1,932,586 | $31,682 |
| Sovaldi | 22 | $623,364 | $28,335 |
| Epclusa | 14 | $342,104 | $24,436 |
| Xifaxan | 161 | $314,978 | $1,956 |
| Daklinza | 12 | $254,015 | $21,168 |
| Ursodiol | 217 | $69,390 | $320 |
| Tacrolimus | 402 | $65,874 | $164 |
| Viread | 49 | $43,520 | $888 |
| Cellcept | 16 | $41,810 | $2,613 |
| Entecavir | 37 | $30,690 | $829 |
| Mycophenolate Mofetil | 242 | $29,622 | $122 |
| Lamivudine Hbv | 45 | $23,413 | $520 |
| Sirolimus | 38 | $17,808 | $469 |
| Prograf | 44 | $17,482 | $397 |
| Truvada | 12 | $17,421 | $1,452 |
| Mycophenolic Acid | 18 | $16,331 | $907 |
| Lialda | 16 | $10,048 | $628 |
| Nexium | 25 | $8,327 | $333 |
| Ribavirin | 48 | $6,713 | $140 |
| Balsalazide Disodium | 16 | $4,322 | $270 |
| Cyclosporine Modified | 50 | $4,088 | $82 |
| Lactulose | 96 | $3,959 | $41 |
| Gengraf | 18 | $3,874 | $215 |
| Neoral | 13 | $3,610 | $278 |
| Omeprazole | 220 | $3,391 | $15 |
| Azathioprine | 32 | $3,079 | $96 |
| Spironolactone | 122 | $2,783 | $23 |
| Amiloride | 46 | $2,219 | $48 |
| Esomeprazole Magnesium | 16 | $1,666 | $104 |
| Fludrocortisone Acetate | 82 | $1,582 | $19 |
| Propranolol | 51 | $1,145 | $22 |
| Furosemide | 172 | $829 | $5 |
| Levothyroxine | 62 | $781 | $13 |
| Escitalopram | 20 | $620 | $31 |
| Pantoprazole | 43 | $612 | $14 |
| Ondansetron | 14 | $608 | $43 |
| Potassium Chloride | 23 | $533 | $23 |
| Promethazine | 14 | $495 | $35 |
| Amlodipine Besylate | 52 | $494 | $9 |
| Metoprolol | 28 | $466 | $17 |
| Warfarin | 41 | $421 | $10 |
| Klor-Con M20 | 22 | $385 | $17 |
| Generlac | 14 | $371 | $27 |
| Tamsulosin | 11 | $308 | $28 |
| Tramadol | 20 | $297 | $15 |
| Sertraline | 56 | $262 | $5 |
| Metoprolol | 52 | $254 | $5 |
| Sulfamethoxazole-Trimethoprim | 27 | $250 | $9 |
| Carvedilol | 41 | $242 | $6 |
| Famotidine | 21 | $234 | $11 |
| Pravastatin | 13 | $203 | $16 |
| Gabapentin | 14 | $202 | $14 |
| Prednisone | 19 | $142 | $7 |
| Ciprofloxacin | 22 | $141 | $6 |
| Torsemide | 16 | $112 | $7 |
| Trazodone | 19 | $101 | $5 |
| Lisinopril | 20 | $97 | $5 |
| Atenolol | 15 | $91 | $6 |
2015: 67 drugs
| Harvoni | 225 | $7,257,774 | $32,257 |
| Sovaldi | 37 | $1,088,353 | $29,415 |
| Daklinza | 17 | $395,716 | $23,277 |
| Viekira Pak | 13 | $367,790 | $28,292 |
| Xifaxan | 164 | $270,552 | $1,650 |
| Ursodiol | 245 | $84,329 | $344 |
| Tacrolimus | 346 | $72,174 | $209 |
| Entecavir | 38 | $47,567 | $1,252 |
| Viread | 64 | $41,398 | $647 |
| Cellcept | 16 | $39,434 | $2,465 |
| Sirolimus | 53 | $35,319 | $666 |
| Mycophenolate Mofetil | 250 | $30,770 | $123 |
| Prograf | 52 | $27,762 | $534 |
| Lamivudine Hbv | 44 | $24,242 | $551 |
| Ribavirin | 69 | $19,553 | $283 |
| Truvada | 12 | $16,512 | $1,376 |
| Nexium | 33 | $15,213 | $461 |
| Rapamune | 16 | $13,882 | $868 |
| Lialda | 13 | $8,336 | $641 |
| Nuvigil | 12 | $7,523 | $627 |
| Cyclosporine Modified | 54 | $6,516 | $121 |
| Spironolactone | 165 | $4,241 | $26 |
| Lactulose | 90 | $3,549 | $39 |
| Balsalazide Disodium | 30 | $3,384 | $113 |
| Azathioprine | 44 | $2,971 | $68 |
| Ribasphere | 23 | $2,960 | $129 |
| Omeprazole | 178 | $2,548 | $14 |
| Fludrocortisone Acetate | 66 | $1,384 | $21 |
| Amiloride | 21 | $1,279 | $61 |
| Ondansetron | 25 | $1,180 | $47 |
| Mirtazapine | 29 | $1,152 | $40 |
| Klor-Con M20 | 30 | $911 | $30 |
| Furosemide | 218 | $853 | $4 |
| Tamsulosin | 26 | $849 | $33 |
| Synthroid | 25 | $799 | $32 |
| Levothyroxine | 74 | $789 | $11 |
| Pantoprazole | 59 | $771 | $13 |
| Warfarin | 51 | $706 | $14 |
| Pravastatin | 25 | $702 | $28 |
| Escitalopram | 17 | $693 | $41 |
| Propranolol | 30 | $662 | $22 |
| Metoprolol | 28 | $525 | $19 |
| Lansoprazole | 11 | $519 | $47 |
| Amlodipine Besylate | 78 | $516 | $7 |
| Hydroxyzine | 24 | $514 | $21 |
| Sulfamethoxazole-Trimethoprim | 61 | $491 | $8 |
| Metoprolol | 87 | $451 | $5 |
| Valsartan-Hydrochlorothiazide | 15 | $439 | $29 |
| Gabapentin | 24 | $417 | $17 |
| Temazepam | 14 | $411 | $29 |
| Generlac | 14 | $392 | $28 |
| Potassium Chloride | 17 | $381 | $22 |
| Tramadol | 44 | $376 | $9 |
| Sertraline | 58 | $314 | $5 |
| Oxycodone | 14 | $277 | $20 |
| Doxepin | 14 | $253 | $18 |
| Peg 3350-Electrolyte | 16 | $252 | $16 |
| Carvedilol | 45 | $218 | $5 |
| Prednisone | 24 | $196 | $8 |
| Ciprofloxacin | 30 | $177 | $6 |
| Promethazine | 17 | $164 | $10 |
| Trazodone | 21 | $77 | $4 |
| Lisinopril | 18 | $76 | $4 |
| Citalopram Hbr | 11 | $67 | $6 |
| Clopidogrel | 11 | $60 | $5 |
| Atenolol | 12 | $48 | $4 |
| Glipizide | 11 | $44 | $4 |
2014: 70 drugs
| Sovaldi | 198 | $5,685,932 | $28,717 |
| Olysio | 71 | $1,613,795 | $22,730 |
| Harvoni | 31 | $995,009 | $32,097 |
| Xifaxan | 252 | $368,644 | $1,463 |
| Tacrolimus | 309 | $84,583 | $274 |
| Ursodiol | 244 | $65,694 | $269 |
| Valcyte | 13 | $53,864 | $4,143 |
| Baraclude | 29 | $49,172 | $1,696 |
| Prograf | 70 | $45,875 | $655 |
| Cellcept | 16 | $36,514 | $2,282 |
| Viread | 44 | $36,102 | $820 |
| Nexium | 70 | $32,002 | $457 |
| Mycophenolate Mofetil | 172 | $28,760 | $167 |
| Rapamune | 25 | $27,937 | $1,117 |
| Lamivudine Hbv | 56 | $22,977 | $410 |
| Entecavir | 13 | $22,405 | $1,723 |
| Truvada | 12 | $15,748 | $1,312 |
| Ribasphere | 90 | $15,248 | $169 |
| Lialda | 20 | $14,774 | $739 |
| Spironolactone | 215 | $6,156 | $29 |
| Cyclosporine Modified | 33 | $5,916 | $179 |
| Cyclosporine | 33 | $5,759 | $175 |
| Sirolimus | 13 | $5,651 | $435 |
| Ribavirin | 35 | $5,245 | $150 |
| Gengraf | 13 | $4,585 | $353 |
| Lactulose | 118 | $4,531 | $38 |
| Omeprazole | 215 | $3,820 | $18 |
| Creon | 15 | $3,574 | $238 |
| Azathioprine | 82 | $3,040 | $37 |
| Neoral | 11 | $2,434 | $221 |
| Lansoprazole | 41 | $1,946 | $47 |
| Amiloride | 24 | $1,607 | $67 |
| Hydrocodone-Acetaminophen | 30 | $1,557 | $52 |
| Fludrocortisone Acetate | 61 | $1,264 | $21 |
| Metoprolol | 34 | $1,251 | $37 |
| Furosemide | 234 | $1,081 | $5 |
| Ondansetron | 16 | $983 | $61 |
| Generlac | 19 | $931 | $49 |
| Pravastatin | 47 | $885 | $19 |
| Hydroxyzine | 13 | $783 | $60 |
| Klor-Con M20 | 38 | $779 | $20 |
| Sertraline | 75 | $757 | $10 |
| Potassium Chloride | 22 | $717 | $33 |
| Levothyroxine | 68 | $713 | $10 |
| Doxepin | 33 | $703 | $21 |
| Synthroid | 24 | $670 | $28 |
| Amlodipine Besylate | 54 | $628 | $12 |
| Pantoprazole | 44 | $622 | $14 |
| Sulfamethoxazole-Trimethoprim | 55 | $505 | $9 |
| Propranolol | 45 | $476 | $11 |
| Escitalopram | 30 | $461 | $15 |
| Metoprolol | 58 | $450 | $8 |
| Valacyclovir | 11 | $392 | $36 |
| Oxycodone | 13 | $316 | $24 |
| Promethazine | 11 | $303 | $28 |
| Warfarin | 52 | $295 | $6 |
| Prednisone | 36 | $283 | $8 |
| Ciprofloxacin | 41 | $270 | $7 |
| Gabapentin | 23 | $259 | $11 |
| Carvedilol | 33 | $235 | $7 |
| Fluoxetine | 18 | $232 | $13 |
| Tramadol | 34 | $225 | $7 |
| Citalopram Hbr | 29 | $171 | $6 |
| Zolpidem | 15 | $162 | $11 |
| Atorvastatin | 14 | $158 | $11 |
| Ranitidine | 19 | $143 | $8 |
| Clonidine | 17 | $139 | $8 |
| Trazodone | 18 | $69 | $4 |
| Lisinopril | 18 | $38 | $2 |
| Atenolol | 12 | $0 | $0 |
2013: 61 drugs
| Xifaxan | 171 | $235,788 | $1,379 |
| Nexavar | 11 | $83,436 | $7,585 |
| Tacrolimus | 209 | $63,272 | $303 |
| Ursodiol | 273 | $61,941 | $227 |
| Baraclude | 22 | $42,055 | $1,912 |
| Prograf | 59 | $40,333 | $684 |
| Viread | 44 | $33,700 | $766 |
| Cellcept | 16 | $33,545 | $2,097 |
| Nexium | 77 | $26,673 | $346 |
| Rapamune | 17 | $26,470 | $1,557 |
| Mycophenolate Mofetil | 138 | $22,874 | $166 |
| Epivir Hbv | 45 | $22,185 | $493 |
| Opium Tincture | 11 | $6,683 | $608 |
| Spironolactone | 205 | $6,639 | $32 |
| Cyclosporine Modified | 22 | $6,165 | $280 |
| Gengraf | 22 | $5,114 | $232 |
| Omeprazole | 189 | $4,335 | $23 |
| Cyclosporine | 12 | $3,548 | $296 |
| Lactulose | 71 | $3,220 | $45 |
| Azathioprine | 93 | $2,855 | $31 |
| Escitalopram | 42 | $2,838 | $68 |
| Neoral | 12 | $2,650 | $221 |
| Lansoprazole | 32 | $2,164 | $68 |
| Potassium Chloride | 26 | $1,839 | $71 |
| Valacyclovir | 13 | $1,642 | $126 |
| Metoprolol | 45 | $1,585 | $35 |
| Klor-Con M20 | 54 | $1,521 | $28 |
| Generlac | 24 | $1,414 | $59 |
| Furosemide | 220 | $1,312 | $6 |
| Sertraline | 112 | $1,203 | $11 |
| Fludrocortisone Acetate | 51 | $1,103 | $22 |
| Pantoprazole | 58 | $921 | $16 |
| Levothyroxine | 106 | $819 | $8 |
| Propranolol | 69 | $757 | $11 |
| Hydroxyzine | 12 | $746 | $62 |
| Hydrocodone-Acetaminophen | 24 | $738 | $31 |
| Gabapentin | 36 | $693 | $19 |
| Enulose | 13 | $635 | $49 |
| Quetiapine | 12 | $597 | $50 |
| Sulfamethoxazole-Trimethoprim | 65 | $577 | $9 |
| Venlafaxine | 13 | $440 | $34 |
| Ondansetron | 14 | $417 | $30 |
| Metoprolol | 57 | $403 | $7 |
| Pravastatin | 34 | $374 | $11 |
| Doxepin | 24 | $372 | $15 |
| Clonidine | 25 | $341 | $14 |
| Amlodipine Besylate | 33 | $332 | $10 |
| Zolpidem | 45 | $326 | $7 |
| Citalopram Hbr | 38 | $318 | $8 |
| Triazolam | 13 | $293 | $23 |
| Ranitidine | 16 | $248 | $15 |
| Peg-3350 With Flavor Packs | 13 | $246 | $19 |
| Warfarin | 27 | $201 | $7 |
| Oxycodone | 13 | $190 | $15 |
| Ciprofloxacin | 35 | $158 | $5 |
| Carvedilol | 16 | $145 | $9 |
| Tramadol | 17 | $141 | $8 |
| Prednisone | 23 | $135 | $6 |
| Trazodone | 17 | $94 | $6 |
| Lisinopril | 19 | $68 | $4 |
| Atenolol | 11 | $26 | $2 |
Money from drug and device companies
$24,686 in 2025
| 2025 | 6 | 20 | $22,475 | $24,686 |
| 2024 | 4 | 16 | $16,189 | $21,057 |
| 2023 | 2 | 16 | $10,310 | $11,390 |
| 2022 | 3 | 9 | $15,309 | $15,622 |
| 2021 | 4 | 8 | $17,868 | $17,981 |
| 2020 | 5 | 7 | $22,460 | $22,460 |
| 2019 | 8 | 36 | $33,652 | $36,829 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novo Nordisk | None | $10,464 | 6 payments
|
| Gilead Sciences | Livdelzi | $4,986 | 7 payments
|
| GlaxoSmithKline | None | $3,600 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $2,621 | 3 payments
|
| Genentech | None | $2,415 | 1 payment
|
| Amgen | Uplizna | $600 | 1 payment
|
See all 20 published payments
| GlaxoSmithKline | Consulting · 2025-11-24 | None | $3,200 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-11-08 | Xifaxan | $131 |
| Gilead Sciences | Consulting · 2025-08-27 | None | $4,040 |
| Gilead Sciences | Travel · 2025-08-27 | None | $58 |
| Gilead Sciences | Travel · 2025-08-27 | None | $58 |
| Gilead Sciences | Travel · 2025-08-27 | None | $36 |
| Gilead Sciences | Travel · 2025-07-29 | None | $304 |
| Gilead Sciences | Travel · 2025-07-28 | None | $350 |
| Novo Nordisk | Travel · 2025-06-24 | None | $233 |
| Novo Nordisk | Travel · 2025-06-24 | None | $307 |
| Novo Nordisk | Travel · 2025-06-24 | None | $28 |
| Novo Nordisk | Travel · 2025-06-24 | None | $327 |
| Novo Nordisk | Meals · 2025-06-24 | None | $150 |
| Novo Nordisk | Consulting · 2025-06-24 | None | $9,420 |
| Gilead Sciences | Meals · 2025-05-05 | Livdelzi | $140 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-04-10 | Xifaxan | $91 |
| GlaxoSmithKline | Consulting · 2025-03-25 | None | $400 |
| Salix Pharmaceuticals a division of Bausch Health US | Consulting · 2025-03-19 | Xifaxan | $2,400 |
| Genentech | Consulting · 2025-01-23 | None | $2,415 |
| Amgen | Consulting · 2025-01-07 | Uplizna | $600 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $21,057
| Novo Nordisk | None | $14,480 | 10 payments
|
| Gilead Sciences | Vemlidy | $6,401 | 3 payments
|
| Exact Sciences | None | $126 | 2 payments
|
| Novo Nordisk AS | None | $50 | 1 payment
|
2023: $11,390
| Gilead Sciences | Vemlidy | $10,090 | 15 payments
|
| Abbvie | None | $1,300 | 1 payment
|
2022: $15,622
| Gilead Sciences | Epclusa | $7,023 | 6 payments
|
| Mallinckrodt Hospital Products | None | $5,799 | 2 payments
|
| GlaxoSmithKline | None | $2,800 | 1 payment
|
2021: $17,981
| Gilead Sciences | None | $6,884 | 3 payments
|
| Mallinckrodt Hospital Products | None | $6,568 | 2 payments
|
| Eisai | Lenvima | $2,580 | 1 payment
|
| AbbVie | Mavyret | $1,950 | 2 payments
|
2020: $22,460
| Janssen Research & Development | None | $8,750 | 1 payment
|
| Gilead Sciences | Epclusa | $6,160 | 2 payments
|
| Mallinckrodt Hospital Products | None | $3,150 | 1 payment
|
| AbbVie | Mavyret | $2,400 | 2 payments
|
| Merck Sharp & Dohme | Sch-018908 - Ribavirin | $2,000 | 1 payment
|
2019: $36,829
| Ferring Pharmaceuticals | None | $13,181 | 8 payments
|
| AbbVie | Mavyret | $8,454 | 11 payments
|
| Gilead Sciences | Epclusa | $5,711 | 5 payments
|
| Mallinckrodt Enterprises | None | $4,649 | 4 payments
|
| Merck Sharp & Dohme | V934 | $2,546 | 2 payments
|
| Eisai | Lenvima | $2,082 | 4 payments
|
| Allergan | None | $165 | 1 payment
|
| La Jolla Pharmaceutical | None | $42 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Eiger BioPharmaceuticals, Inc. · D-Livr · 2022 | Their institution | $128,375 |
| Takeda Pharmaceuticals U.S.A., Inc. · Study To Check the Safety of Fazirsiran and Learn If Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due To An Abnormal Version of Alpha-1 Antitrypsin Protein · 2025 | Their institution | $117,201 |
| Takeda Pharmaceuticals U.S.A., Inc. · Hepatic Impairment · 2024 | Their institution | $109,596 |
| Allergan, Inc. · Aurora: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis · 2020 | Their institution | $100,088 |
| Bausch Health US, LLC · A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (Ssd) for the Delay of Encephalopathy Decompensation in Cirrhosis · 2024 | Their institution | $88,400 |
| Ultragenyx Pharmaceutical Inc. · Ux701-Cl301 · 2024 | Their institution | $72,818 |
| EIGER BIOPHARMACEUTICALS, INC. · Limt-2 · 2023 | Their institution | $68,717 |
| E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Compensated Liver Cirrhosis · 2020 | Their institution | $51,087 |
| Madrigal Pharmaceuticals · A Phase 3 Multinational Doubleblind Randomized Placebocontrolled Study of Mgl3196 Resmetirom in Patients With Nonalcoholic Steatohepatitis Nash and Fibrosis To Resolve Nash and Reduce Progression To Cirrhosis Andor Hepatic Decompensation · 2025 | Their institution | $44,509 |
| Ultragenyx Pharmaceutical Inc. · Ux701-Cl301 · 2025 | Their institution | $39,823 |
| Janssen Research & Development, LLC · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Deferred Active Treatment To Investigate the Efficacy, Safety, and Pharmacokinetics of Jnj-73763989 + Nucleos(T)Ide Analog in Participants Co-Infected With Hepatitis B and He · 2024 | Their institution | $38,169 |
| Takeda Pharmaceuticals U.S.A., Inc. · Hepatic Impairment · 2025 | Their institution | $37,710 |
| Janssen Research & Development, LLC · A Phase 2, Multicenter, Randomized, Double-Blind, Placebocontrolled Study With Deferred Active Treatment To Investigate the Efficacy, Safety, and Pharmacokinetics of Jnj73763989 + Nucleos(T)Ide Analog in Participants Coinfected With Hepatitis B and Hepatitis D Virus · 2022 | Their institution | $36,274 |
| E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Stage 3 Liver Fibrosis · 2020 | Their institution | $33,944 |
| Allergan Inc. · Aurora A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis · 2019 | Their institution | $31,149 |
| Gilead Sciences, Inc. · A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis · 2021 | Their institution | $30,223 |
| Takeda Pharmaceuticals U.S.A., Inc. · Study To Check the Safety of Fazirsiran and Learn If Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due To An Abnormal Version of Alpha-1 Antitrypsin Protein · 2024 | Their institution | $28,890 |
| EIGER BIOPHARMACEUTICALS, INC. · D-Livr · 2023 | Their institution | $26,981 |
| E.R. Squibb & Sons, L.L.C. · Phase Iib in Nash Mono - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study To Evaluate the Efficacy and Safety of Bms-986263 in Adults With Compensated Cirrhosis From Nonalcoholic Steatohepatitis (Nash) · 2023 | Their institution | $26,217 |
| Ultragenyx Pharmaceutical Inc. · Ux701-Cl301 · 2022 | Their institution | $24,972 |
| Janssen Research & Development, LLC · A Phase 2, Multicenter, Randomized, Double-Blind, Placebocontrolled Study With Deferred Active Treatment To Investigate the Efficacy, Safety, and Pharmacokinetics of Jnj73763989 + Nucleos(T)Ide Analog in Participants Coinfected With Hepatitis B and Hepatitis D Virus · 2023 | Their institution | $22,517 |
| Bausch Health US, LLC · A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (Ssd) for the Delay of Encephalopathy Decompensation in Cirrhosis · 2025 | Their institution | $21,719 |
| AbbVie Inc. · 2020 | Their institution | $20,530 |
| E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 Peg-Fgf21 in Adults With Nonalcoholic Steatohepatitis Nash and Stage 3 Liver Fibrosis · 2019 | Their institution | $19,430 |
| Janssen Research & Development, LLC · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Deferred Active Treatment To Investigate the Efficacy, Safety, and Pharmacokinetics of Jnj-73763989 + Nucleos(T)Ide Analog in Participants Co-Infected With Hepatitis B and He · 2023 | Their institution | $16,561 |
| Novartis Pharmaceuticals Corporation · Two Part Randomized Double Blind Placebo Controlled Multicenter Dose Ranging and Confirmatory Study To Assess the Safety and Efficacy of Vay736 in Autoimmune Hepatitis Patients With Incomplete Response To Or Intolerance of Standard Therapy Amber · 2021 | Their institution | $13,696 |
| AbbVie, Inc. · 2019 | Their institution | $13,641 |
| Allergan, Inc. · Aurora: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis · 2021 | Their institution | $13,351 |
| Takeda Pharmaceuticals U.S.A., Inc. · Tak-999-3002 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With Metavir Stage F1 Fibrosis · 2025 | Their institution | $9,407 |
| E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Stage 3 Liver Fibrosis · 2021 | Their institution | $8,765 |
| Janssen Research & Development, LLC · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Deferred Active Treatment To Investigate the Efficacy, Safety, and Pharmacokinetics of Jnj-73763989 + Nucleos(T)Ide Analog in Participants Co-Infected With Hepatitis B and He · 2025 | Their institution | $8,382 |
| E.R. Squibb & Sons, L.L.C. · Safety and Effectiveness of Bms-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (Nash) · 2024 | Their institution | $7,610 |
| Novartis Pharmaceuticals Corporation · Two Part Randomized Double Blind Placebo Controlled Multicenter Dose Ranging and Confirmatory Study To Assess the Safety and Efficacy of Vay736 in Autoimmune Hepatitis Patients With Incomplete Response To Or Intolerance of Standard Therapy Amber · 2020 | Their institution | $7,140 |
| Gilead Sciences, Inc. · A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis · 2019 | Their institution | $5,336 |
| Allergan, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. · 2020 | Their institution | $5,195 |
| Janssen Research & Development, LLC · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Deferred Active Treatment To Investigate the Efficacy, Safety, and Pharmacokinetics of Jnj-73763989 + Nucleos(T)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus · 2023 | Their institution | $3,864 |
| E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Compensated Liver Cirrhosis · 2022 | Their institution | $3,816 |
| E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 Peg-Fgf21 in Adults With Nonalcoholic Steatohepatitis Nash and Compensated Liver Cirrhosis · 2019 | Their institution | $3,790 |
| La Jolla Pharmaceutical Company · A Phase 2, Multi-Center, Randomized, Placebo Controlled, Double-Blind Study With Ljpc-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis · 2020 | Their institution | $3,302 |
| Gilead Sciences, Inc. · A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, Gs-0976, Gs-9674, and Combinations in Subjects With Bridging (F3) Fibrosis Or Compensated Cirrhosis (F4) Due To Nonalcoholic Steatohepatitis (Nash) · 2019 | Their institution | $3,200 |
| Janssen Research & Development, LLC · A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Deferred Active Treatment To Investigate the Efficacy, Safety, and Pharmacokinetics of Jnj-73763989 + Nucleos(T)Ide Analog in Participants Co-Infected With Hepatitis B · 2025 | Their institution | $2,932 |
| La Jolla Pharmaceutical Company · A Phase 2, Multi-Center, Randomized, Placebo Controlled, Double-Blind Study With Ljpc-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis · 2019 | Their institution | $2,880 |
| E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Stage 3 Liver Fibrosis · 2022 | Their institution | $2,534 |
| ABBVIE INC. · An Open-Label, Multicenter Study To Evaluate Long-Term Outcomes With Abt-450/Ritonavir/Abt-267 (Abt-450/R/Abt-267) and Abt-333 With Or Without Ribavirin (Rbv) in Adults With Genotype 1 Chronic Hepatitis C Virus (Hcv) Infection (Topaz II) · 2021 | Their institution | $2,496 |
| Allergan Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. · 2019 | Their institution | $2,221 |
| E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Stage 3 Liver Fibrosis · 2023 | Their institution | $922 |
| E.R. Squibb & Sons, L.L.C. · Phase Iib in Nash Mono - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study To Evaluate the Efficacy and Safety of Bms-986263 in Adults With Compensated Cirrhosis From Nonalcoholic Steatohepatitis (Nash) · 2022 | Their institution | $903 |
| EIGER BIOPHARMACEUTICALS, INC. · D-Livr · 2022 | Their institution | $900 |
| Allergan, Inc. · Aurora: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis · 2022 | Their institution | $750 |
| E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Compensated Liver Cirrhosis · 2021 | Their institution | $709 |
| Merck Sharp & Dohme Corporation · A Phase III Double Blind Clinical Trial To Study the Efficacy and Safety of the Combination Regimen of Mk-5172 and Mk-8742 in Subjects With Chronic Hcv Gt1, Gt4 and Gt6 Infection With Inherited Blood Disorders With and Without Hiv Co-Infection · 2021 | Their institution | $337 |
| Novartis Pharmaceuticals Corporation · Two Part Randomized Double Blind Placebo Controlled Multicenter Dose Ranging and Confirmatory Study To Assess the Safety and Efficacy of Vay736 in Autoimmune Hepatitis Patients With Incomplete Response To Or Intolerance of Standard Therapy Amber · 2022 | Their institution | $232 |
| MACROGENICS, INC. · Limt-2 · 2024 | Their institution | $96 |
| Novartis Pharmaceuticals Corporation · Two Part Randomized Double Blind Placebo Controlled Multicenter Dose Ranging and Confirmatory Study To Assess the Safety and Efficacy of Vay736 in Autoimmune Hepatitis Patients With Incomplete Response To Or Intolerance of Standard Therapy Amber · 2019 | Their institution | $60 |
| Novartis Pharmaceuticals Corporation · Two Part Randomized Double Blind Placebo Controlled Multicenter Dose Ranging and Confirmatory Study To Assess the Safety and Efficacy of Vay736 in Autoimmune Hepatitis Patients With Incomplete Response To Or Intolerance of Standard Therapy Amber · 2023 | Their institution | $60 |
| E.R. Squibb & Sons, L.L.C. · Phase Iib Study - F3 24 Wk · 2020 | Their institution | $40 |
| E.R. Squibb & Sons, L.L.C. · Phase Iib Study - F4 48 Wk · 2020 | Their institution | $38 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1578527008
- Licence
- CA G145613, IN 01043753California G145613: Current · expires 2027-12-31
- Trained
- Wayne State University School of Medicine, 1988
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- IN 200034940
- Taxonomy
- Federal specialty code 207RI0008X (207RI0008X); Federal specialty code 207RG0100X (207RG0100X); Federal specialty code 207RT0003X (207RT0003X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-04-13
- NPI last updated
- 2026-09-03
- NPI record certified
- 2026-09-03
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1804 Embarcadero Rd, Palo Alto, CA, 94303